4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzoic acid

‌

‌CCMO-48 | USP/EP-Certified Pharmaceutical Intermediate for Oncology & Research‌

‌Key Features‌

• ‌Ultra-High Purity‌

  : ≥99.5% HPLC/GC-MS verified, compliant with 

  ‌USP/EP pharmacopeial standards‌

   for oncology drug development and API synthesis‌14.

• ‌Dual Applications‌

  :

• ‌Oncology Therapeutics‌

  : Critical intermediate for 

  ‌PARP inhibitor APIs‌

   targeting breast, ovarian, and prostate cancers‌46.

• ‌Research Use‌

  : Supports 

  ‌preclinical studies‌

   in DNA repair mechanisms and chemotherapy resistance‌23.

• ‌Stability‌

  : 24-month shelf life under -20°C storage in nitrogen-sealed amber vials‌35.

‌Applications‌

• ‌API Manufacturing‌

  : Enables scalable synthesis of 

  ‌PARP inhibitor drugs‌

   (e.g., Olaparib analogs)‌46.

• ‌Academic & Industrial R&D‌

  : Used in 

  ‌cancer biomarker studies‌

   and 

  ‌targeted therapy optimization‌

  ‌25.

‌Quality Assurance‌

• ‌Regulatory Compliance‌

  : Meets 

  ‌residual solvent (<20 ppm)‌

   and 

  ‌genotoxic impurity (<0.1%)‌

   limits per 

  ‌ICH Q3 guidelines‌

  ‌35.

• ‌Customization‌

  : Available in 

  ‌1g-10kg batches‌

   with optional 

  ‌COA/MSDS documentation‌

  ‌14.

‌Google Keywords‌:

• Bulk CCMO-48 Supplier USP/EP

• Oncology Intermediate API Synthesis

• PARP Inhibitor Raw Material

• *Pharmaceutical-Grade CCMO-48 99.5%*‌12.